Since Food and Drug Administration's approval of the HeartMate II left ventricular assist device (LVAD) as destination therapy, the number of hospitals offering LVAD therapy has grown rapidly. A rising number are performed at centers without internal transplant programs. We sought to determine whether outcomes after destination therapy LVAD implantation are similar at transplant and nontransplant centers. 
T
he population of patients with a left ventricular assist device (LVAD) and number of implanting centers have grown rapidly in the past decade. 1 Juxtaposing the limited number of donor hearts available for transplantation 2 with the growing number of potential candidates eligible for advanced therapies, 3 the growth in volume of patients supported by these technologies and the number of providers caring them is likely to continue. The landmark REMATCH trial (Randomized Evaluation of Mechanical Assistance for Treatment of Congestive Heart Failure) first demonstrated that patients ineligible for heart transplantation had improved survival with a first-generation pulsatile LVAD compared with optimal medical therapy alone. 4 The HeartMate II investigators subsequently demonstrated incremental survival benefit with a second-generation, continuous-flow (CF) LVAD compared with the firstgeneration pulsatile platform. 5 Beyond survival, studies have also demonstrated that destination therapy (DT) LVAD therapy improves health-related quality of life (HRQL) and functional capacity. 5, 6 Since the Food and Drug Administration's approval of the HeartMate II device for DT in 2010, the proportion of LVADs implanted for this indication has risen to 46% of annual implants. 1 Identifying ways to improve patient outcomes and reduce complications for this costly therapy is, thus, a priority.
An increasing volume of medical centers are able to offer DT LVAD surgery outside of the framework of a traditional cardiac transplant program-so-called Destination Therapy Centers. 7 This structure allows greater access to this life-saving technology to patients who may otherwise have geographic barriers to therapy given the burden of care associated with the long-term monitoring required at the implanting center. The present dogma is similar to what has evolved with other technologies that were initially available only at select hospitals, with expanded access over time to other specialized centers. It is well established that multidisciplinary teams are essential to ensure optimal outcomes for patients undergoing complex cardiac interventions. 8 All LVAD centers, regardless of transplant capabilities, are similarly required to have multidisciplinary heart failure teams to guide patient selection and assist in the long-term care of this unique population. 9 Whether the construct of a transplant center is associated with differences in long-term outcomes after LVAD implantation has not yet been fully investigated. Our primary aim was to compare outcomes among LVAD recipients implanted at centers with and without associated cardiac transplant programs.
METHODS

Population
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results because of a data use agreement. The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) is a prospective registry of approved durable mechanical circulatory support devices implanted in the North America. A full description is available at http://www. INTERMACS.org. The INTERMACS protocol was approved by the National Institutes of Health and the Institutional Review Boards at each participating center. Adult (aged >18 years) recipients of a primary, CF-LVAD implanted as DT from January 2012 through March 2014 were included. Patients were excluded if they underwent biventricular assist device implantation or if they were undergoing LVAD exchange. Implanting centers were categorized as transplant or nontransplant centers by INTERMACS. Center volume was categorized as <15 or ≥15 total implants before 2012. 10 A sensitivity analysis alternatively categorized implant center volume for the 2011 calendar year as <10, 11 to 20, 21 to 30, and >30 procedures.
Outcomes
The primary outcome was patient survival, censored at device explant for recovery or transplant. Secondary outcomes included freedom from death or major adverse events, individual adverse event rates, hospitalization, and HRQL assessed with the EQ-5D (EuroQol) tool visual analog score (VAS) at 6 months. Major adverse events were defined according to the INTERMACS protocol definitions and included major bleeding (major internal or external bleeding resulting in death, reoperation, hospitalization, or transfusion), device infection (driveline, pocket, or pump), device malfunction, device exchange (for malfunction, infection, or thrombosis), right heart failure (need for right VAD, inotrope, or vasodilator beyond 7 days from implant or 2 signs/symptoms), and stroke (hemorrhagic, ischemic, or other).
WHAT IS NEW?
• Among 3583 patients in the Interagency Registry for Mechanically Assisted Circulatory Support with a continuous-flow ventricular assist device implanted as destination therapy, short-and long-term survival was similar at transplant and nontransplant centers even after adjustment for established risks and volume.
• Adverse event rates, rehospitalization, and postimplant quality of life scores were also similar.
WHAT ARE THE CLINICAL IMPLICATIONS?
• In their respective populations, nontransplant centers and transplant centers implanting modern continuous-flow ventricular assist devices as destination therapy had comparable morbidity and mortality.
• Under current guidelines for patient selection, experience, and multidisciplinary care, access to destination therapy has expanded with preserved quality in key outcomes.
Composite adverse events were censored at the first event, explant for recovery, or transplant. Individual events were censored at death, explant for recovery, or transplant.
Statistical Analysis
Variables are expressed as percent (frequency) if categorical and median (interquartile range) if continuous. Statistics were performed using SAS 9.4 (SAS, Cary, NC) and graphs prepared using STATA 14.2 (Stata Corp, College Station, TX). Groups were compared using χ 2 test and Student t test or Wilcoxon ranksum test as appropriate. There was no missing data for mortality or major adverse events. There was missing data in either pre-or postimplant quality of life scores for 64% of records. There was <10% missing data for baseline variables, except hemodynamic parameters (up to 41% missing) and cardiac resynchronization therapy (43% missing). Multiple imputation was used for records with <50% missing data using the SAS MI procedure. Values beyond the 2.5th and 97.5th percentiles post-imputation were truncated at these values, respectively, to eliminate the influence of outliers. Kaplan-Meier curves were generated for time-to-event analyses and compared with the log-rank test. Cox proportional hazards regression was used for multivariable analysis of the primary and secondary outcomes with the imputed data set. Candidate variables were selected a priori for inclusion in the Cox model based on prior association with mortality, in addition to the variables of interest, center status, and center volume. 1, 10, 11 The midpoint of age categories was used to estimate a continuous hazard ratio (HR). A global test of proportional hazards was performed using the global correlation test on weighted Schoenfeld residuals. Postimplantation EQ-5D VAS were adjusted for preimplantation VAS and baseline variables using multiple linear regression without imputation. Patients who died before follow-up were assigned the worst score of zero.
RESULTS
Baseline Characteristics
A total of 3583 patients with CF-LVADs were implanted as DT within the study period, with 260 at nontransplant centers and 3323 at transplant centers ( Figure 1 ). Preimplant characteristics are listed in Table 1 . Patients implanted at nontransplant centers were different than those implanted at transplant centers. Nontransplant center patients tended to be older, have higher body mass index, and were more likely have an ischemic cause of heart failure. The nontransplant center cohort was generally less sick with higher average INTERMACS patient profiles (P=0.04), more normal laboratory and hemodynamic values, less commonly received preimplant intra-aortic balloon pump support, and more commonly receiving standard oral neurohormonal antagonist therapies. Patients at nontransplant centers were also more likely to undergo implantation at lower volume centers (<15 total implants before 2012). Despite this, the majority of patients in both groups had LVAD surgery at centers with total cumulative volume of experience ≥15 implants. All nontransplant centers had <21 LVAD implants in 2011.
Outcomes
Median duration of support was 12.1 months. Patient survival as compared by Kaplan-Meier curves was not significantly different between cohorts ( Figure 2 ; logrank P=0.30). Estimated 1-month survival for nontransplant and transplant cohorts were 94.2% (95% confidence interval [CI], 97.1-93.4) and 94.2% (95% CI, 95.0-93.4), whereas 12-month survival was 71.3% and 76.4%, respectively. Freedom from death or major adverse event was also not significantly different between center types ( Figure 3 ; log-rank P=0.47), with estimated rates at various time points listed. The most common adverse events were bleeding and right heart failure. Rates of individual adverse events including bleeding, device infection, device malfunction, pump exchange, right heart failure, and stroke were not significantly different (Table 2 ). Finally, rehospitalization was common for both groups but not significantly different between populations-the proportion of LVAD patients requiring rehospitalization during long-term follow-up was 77% at nontransplant centers and 75% at transplant centers (P=0.74).
Multivariate and Subgroup Analyses
Cox proportional hazards modeling of mortality (Table 3) demonstrated that center type was not associated with Because the majority of transplant centers had higher volumes than nontransplant centers, a subgroup analysis compared patients implanted at centers with similar volume. Within the cohort limited to centers with volume <21 primary implants in 2011, 198 patients were from nontransplant centers and 1206 from transplant centers. Neither patient survival (log-rank P=0.22) nor freedom from death or major adverse event (log-rank P=0.84) was different between these groups. Twelvemonth survival was 71.8% (64.9%-78.6%) at nontransplant centers compared with 76.6% (74%-79.2%) at transplant centers, whereas freedom from death or major adverse event was 29.8% (22.9%-36.7%) versus 29.9% (27.1%-32.7%), respectively.
Quality of Life
Median preimplant VAS was 45 (interquartile range, 25-60) at nontransplant centers and 41.5 (25-60) at transplant centers, which increased at 6 months postimplant to 68.5 (0-80) and 70 (0-85), respectively. To account for the effect of preimplant on postimplant HRQL, multiple linear regression was performed ( Values are represented as % (n) or median (interquartile range). ACEI indicates angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BP, blood pressure; BUN, blood urea nitrogen; CRT, cardiac resynchronization therapy; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; INR, international normalized ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PA, pulmonary artery; PCW, pulmonary capillary wedge; PDE, phosphodiesterase; RA, right atrium; SGOT, serum glutamic oxaloacetic transaminase; and SGPT, serum glutamic pyruvic transaminase. 
DISCUSSION
The primary finding of this study is that outcomes after DT LVAD surgery are similar for patients whether implanted at transplant or nontransplant centers. Although patients undergoing implantation at transplant centers tended to be sicker, adjusting for baseline markers of disease severity did not lead to a difference in outcomes between center types. Risk factors adjusted for in the multivariable model included variables identified in the HeartMate II risk score, 10 DT risk score, 12 and prior INTERMACS investigations. 1 Major adverse event rates reported in the current analyses correspond to those previously published for DT patients (68%-76% at 12 months) from INTERMACS and HeartMate II clinical trials. 1, 5, 6 Likewise, patients had similar improvement in HRQL whether implanted at nontransplant versus transplant centers, despite potential advantages of closer proximity and greater provider continuity at nontransplant programs. To our knowledge, this study represents the first direct comparison of outcomes for DT LVAD recipients at nontransplant and transplant centers.
Katz et al 13 recently described 276 LVAD patients, including bridge to transplant and DT indications, implanted at 27 nontransplant centers. Twelve-month survival (92% for bridge to transplant recipients and 70% for DT recipients) and adverse event rates were similar to those reported for historical controls; however, no control arm was available. Using data from the INTERMACS registry, we add to these findings by comparing event rates for DT LVAD recipients implanted at nontransplant and transplant centers. The DT population was specifically chosen for comparison because bridge to transplant recipients implanted at nontransplant centers are more likely receive care across institutions (shared care), which would dilute a center-specific effect on care. 9 Thus, comparisons including bridge to transplant patients are less likely to reflect the comparison of interest, center typespecific outcomes. Although DT patients implanted at a transplant center may eventually transition their care to nontransplant centers, relative to the large denominator of transplant center of DT implants, this presumably smaller cohort of patients was felt unlikely to significantly bias the primary findings of this investigation.
Contemporary cohorts of non-inotrope-dependent, ambulatory, advanced heart failure patients (Ameri- can Heart Association Stage D) continue to experience 12-month mortality as high as 18% to 23% when treated with medical therapy alone. 14, 15 The finite number and geographic distribution of heart-transplant centers have historically limited LVAD therapy to patients living in close proximity to transplant centers or to those with the financial and social means to travel great distances for care. The number of hospitals enrolled in INTERMACS almost doubled from 88 in 2009 to 158 in 2014, with a concomitant increase in the proportion of total implants listed as DT rising from 9% to 46%. 1, 16 The growing volume of DT centers serves to increase access to additional patients who may benefit from LVAD support.
Given the adverse event burden associated with LVAD therapy, as expertise in mechanical circulatory support disseminates to an increasing number of hospitals, it remains important to ensure a high quality of care. A large, multidisciplinary team is required to manage this complex patient population during the implant procedure and during long-term follow-up. 17 Complications associated with mechanical circulatory support span across disciplines and include neurological, infectious, and gastrointestinal bleeding complications. Although transplant centers by default have established multidisciplinary teams, it is possible that these teams are less established at emerging DT centers, which could affect outcomes associated with this highly specialized intervention.
Assuming the appropriate infrastructure is in place, the findings of the present study should mitigate concerns on broader extension of this therapy, as has occurred with other emerging technologies including transcutaneous valve procedures. [18] [19] [20] These results from INTERMACS demonstrate that expanded access to this restorative and life-saving therapy to nontransplant centers has occurred while maintaining high-quality patient outcomes.
Although nontransplant centers on average had lower volume, survival remained similar despite attempts to adjust for volume. Furthermore, restricting the analyses to the subgroup of transplant centers with comparable volume to nontransplant centers did not alter the primary findings. In contrast to previous investigations, center volume was not identified as an independent predictor of survival. 10 Shah et al 21 analyzed the National Inpatient Sample and found that hospital volume was a significant predictor of inpatient mortality, with the optimal threshold of at least 20 LVADs per year. For the baseline period analyzed here, all nontransplant centers were comparatively low volume. Similarly, Davis et al 22 analyzed a large administrative database and found that surgeon volume rather than hospital volume was a significant predictor of in-hospital mortality. The relationship between surgeon volume and survival, however, was modest. Nevertheless, there are important caveats that limit comparison of these prior studies with the current investigation. First, we used Kaplan-Meier freedom from death or major adverse event with number at risk and estimates at specified times, censored for transplant or explant for recovery. Major adverse events include death, stroke, major bleeding, pump exchange, device infection, device malfunction, and right heart failure.
established predictors of mortality including laboratory and hemodynamic data in addition to INTERMACS patient profile, metrics not available in administrative data. Second, these prior investigations also included first-generation pulsatile-flow devices, potentially limiting generalizability to the modern era. This is reflected by the relatively low short-term mortality rate (5.8% at 30 days) found in the present analysis of CF-LVAD recipients. Improved survival likely reflects improvements in technology, patient selection, and management compared with previous eras. As past studies illustrate, surgical volume is most likely to affect early outcomes related to technique or perioperative care. Despite this, we found no differences in short-term survival between transplant and nontransplant centers.
With the rapidly evolving toolbox of available technologies, optimal patient selection and commitment of institutional resources necessary to support this unique and growing patient population is critical, regardless of center type. This holds especially true for DT candidates whose baseline comorbidities and longer duration of support provide greater exposure time for experiencing adverse events. Furthermore, because transplantation is not typically available as a bailout strategy in the DT patients should an adverse event occur, there is greater emphasis on HRQL associated with LVAD therapy in this population. Because some patients initially implanted as DT may later become eligible for transplantation (ie, after resolution of pulmonary hypertension), ongoing partnerships between nontransplant and transplant centers remains important to ensure ongoing, optimal patient-centered care.
Limitations
This study has several limitations, principally those common to post hoc registry analyses. As centers begin DT programs, they may select patients with lower risk profiles compared with established centers, creating selection bias. It is not possible to adjust for residual confounders, and it remains possible that outcomes are different between center types despite attempts to adjust for center volume and risk factors for adverse events. Furthermore, the degree of missing data was substantial for the secondary outcome of HRQL and a few preimplant variables. Data that is not missing at random can introduce bias into the study results, although this should be minimized by statistical methodology using multiple imputation. Kaplan-Meier adverse event rate estimates with (95% confidence interval), censored for death, transplant, or explant for recovery. Hospitalization rate is also shown. P value is for log-rank comparison. Furthermore, as discussed elsewhere, models of shared care were unable to be accounted for and could bias the results toward the null. Although we attempted to adjust for volume with 2 methodologies, these methods may not be adequate, specifically at the tails of the volume distribution. Finally, the population was ≈80% male, so generalization to women is a potential limitation.
Conclusions
Approximately 7% of 3583 CF-LVAD implants performed as DT between January 2012 and March 2014 recorded in INTERMACS occurred at nontransplant, DT LVAD centers. Short-and long-term outcomes including survival, adverse events, and quality of life are similar for patients receiving LVAD therapy at transplant versus nontransplant centers.
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